msc2363318a
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 13, 2013 (NCT01971515)
Timeline
2010s
- Jan 1, 2013
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Serine/threonine-protein kinase AKT3INHIBITOR
AKT3 inhibitor
- Serine/threonine-protein kinase AKTINHIBITOR
AKT1 inhibitor
- Ribosomal protein S6 kinase (P70S6K)INHIBITOR
Ribosomal protein S6 kinase (P70S6K) inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
NC(=O)c1cccc2c(N[C@H](CN3CCC3)c3ccc(Cl)c(C(F)(F)F)c3)ncnc12- Mol. weight
- 449.86 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4871106 ↗
- ChEMBLCHEMBL3545003 ↗
Also known as
- msc2363318a
- msc-2363318a
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01971515 | Phase 1 | Dec 13, 2013 | Merck Serono |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck Serono | For profit | 1 | 1 | 1 | 2013 |
1 organizations
Page 1 / 1